Intercept Pharmaceuticals sets IPO terms

By Renaissance Capital,

Shutterstock photo

Intercept Pharmaceuticals, which is focused on the development and commercialization of therapeutics for chronic liver disease, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Intercept Pharmaceuticals would command a market value of $210 million. 

Intercept Pharmaceuticals, which was founded in 2002 and booked $3 million in revenue for the 12 months ended June 30, 2012, plans to list on the NASDAQ under the symbol ICPT. BofA Merrill Lynch is the lead bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ICPT

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by